NHS England has approved mirvetuximab soravtansine, also known as Elahere, for some women in England with ovarian, peritoneal or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The treatment is aimed at tumours carrying the FRα protein it targets, and the health service says up to 400 women a year could now benefit.
The decision matters because it gives clinicians a new option for a group of patients who have had very few effective choices for more than 20 years. Ruth Plummer said the approval would offer hundreds of women precious extra time with their loved ones, calling it the most significant breakthrough in NHS treatment for these hard-to-treat cancers in over two decades.
The timing is important for another reason: this is the first new NHS-approved drug for chemotherapy-resistant ovarian cancer in 20 years. The treatment is given by drip once every three weeks, and it comes after a global clinical trial involving eight NHS hospitals found it delayed cancer progression and prolonged survival by an average of four months compared with chemotherapy.
That trial also found tumours shrank by at least 30% in 37% of patients, compared with 16% for chemotherapy. The drug, made by AbbVie, combines an antibody with a cancer-killing molecule, a design meant to deliver treatment more directly to the cancer cells that carry the target protein.
The need for a new option is plain. Ovarian cancer affects more than 300,000 women a year globally and is the 18th most common cancer worldwide. More than three-quarters of patients are diagnosed at an advanced stage, about 80% of those with advanced disease relapse, and most eventually become resistant to chemotherapy.
That is why mirvetuximab soravtansine stands out now: it is being introduced into a space where patients with folate receptor-alpha-positive platinum-resistant epithelial cancers have long had limited help when standard chemotherapy stops working. NHS England has not set out when eligible patients will begin receiving it, but the approval clears the way for it to be offered through the service in England.
